Pharmacological Therapy

In Children, Reduced Arousal Aggravates Respiratory Depression By Morphine

June 11, 2015

Reporting on a study of the reaction of children to morphine administration at SLEEP 2015, Gaspard Montandon, PhD, University of Toronto, said that respiratory depression was "more severe when patients were in states of reduced arousal due to the sedative properties of morphine."

How Does OSAS Severity Affect Glucose Tolerance?

June 11, 2015

Severe obstructive sleep apnea syndrome (OSAS) may potentially be associated with pancreatic β-cell functional disorder and glucagon-like peptide-1 (GLP-1) resistance, according to a study presented at SLEEP 2015.

Chew on This: Caffeine Gum Put to the Test in New Study

By June 11, 2015

Chewing caffeine gum for five minutes immediately upon awakening may counter sleep inertia, especially for reaction time, according to a data presented at SLEEP 2015.

Some Sedative Hypnotics Not Ideal for Predicting Low-Arousal Threshold

By June 11, 2015

Administration of a non-benzodiazepine sedative hypnotic (NBSH) does not increase the likelihood of having a low arousal phenotype for obstructive sleep apnea (OSA), a study presented at SLEEP 2015 has concluded.

Study: Suvorexant Improves Sleep, Daytime Functioning at Two Doses

June 11, 2015

The orexin receptor antagonist suvorexant improves sleep in patients with insomnia, analysis of pooled results of two Phase 3 clinical trials presented at SLEEP 2015 have found.

Lemborexant Shows Equivalent Efficacy in Men, Women With Insomnia

By June 11, 2015

Lemborexant (E2006), a dual orexin receptor antagonist (DORA) under development for insomnia disorder, led to a decrease in latency to persistent sleep (LPS) and wake after sleep onset (WASO) and an increase in sleep efficiency (SE), according to data presented at SLEEP 2015.

Sodium Oxybate Found to Improve Health-Related Quality of Life Measures

By June 11, 2015

Sodium oxybate improved health-related quality-of-life (HRQoL) measures in patients with narcolepsy in a dose-dependent manner, results from a randomized placebo-controlled trial presented at SLEEP 2015 have found.

Pharmacotherapy Improves Function in Patients With Narcolepsy in 'Real-World' Setting

By June 11, 2015

Pharmacotherapy improves multiple domains of functioning in patients with central disorders of hypersomnolence (CDH) in a "real-world" tertiary care setting, according to data presented at SLEEP 2015.

Flu Vaccine Triggers Status Cataplecticus in Teen With Narcolepsy

By June 11, 2015

A case study presented at SLEEP 2015 suggest that an influenza vaccination may have triggered status cataplecticus in the female patient with known narcolepsy.

SSRI Could Improve Sleep via Fibromyalgia Relief

By June 11, 2015

Milnacipran does not directly improve sleep continuity and architecture but its impact on sleep improvement can be attributed to its effectiveness in reducing pain, according to data presented at SLEEP 2015.

Longer Sleep May Have Protective Effect on Pain

By June 11, 2015

Endogenous pain regulatory function is impacted by sleep duration, according to data presented at SLEEP 2015,

Comparable Effects Seen With Zolpidem, Eszopiclone in PAP Titration

June 10, 2015

When eszopiclone was given instead of zolpidem, no difference was observed on the polysomnogram diagnostic and positive airway pressure (PAP)-titration portions, according to data reported at SLEEP 2015.

Case Study: New Onset Myasthenia Gravis and Narcolepsy With Cataplexy

By June 10, 2015

An 80-year-old male with new onset myasthenia gravis and narcolepsy with cataplexy had symptomatic improvement with sodium oxybate—but not with immune-modulating agents, results of a case study presented at SLEEP 2015 have shown.

Novel DORA Agent Promising As Insomnia Treatment

By June 10, 2015

E2006, a novel dual orexin receptor antagonist (DORA), has shown efficacy for both subject-reported sleep onset and maintenance on sleep diary measures, according to Phase 2 study results reported at SLEEP 2015.

Fewer Cognitive Effects Seen With Almorexant Than BZD Receptor Agonists

By June 10, 2015

Almorexant, a hypocretin receptor antagonist, produced fewer acute cognitive effects than the GABAA receptor modulator zolpidem, according to results of a randomized controlled trial presented at SLEEP 2015.

Two Gabapentin Enacarbil Doses Found to Reduce Pain, RLS Symptoms

By June 10, 2015

Treatment with gabapentin enacarbil at both the 600mg and 1200mg doses "led to a greater number of adult patients who met the criteria for a combined pain and International Restless Legs Scale (IRLS) total score response" compared to placebo, a study presented at SLEEP 2015 confirmed.

Factors Identified in Zolpidem Treatment Failure for Insomnia

By June 10, 2015

For about one-third of patients treated with zolpidem, only partial improvement is observed, researchers reported at SLEEP 2015.

Does Vitamin E Increase Memory Performance in Sleep-Deprived Patients?

June 09, 2015

Higher levels of vitamin E improve spatial memory performance in sleep-deprived women, according to data presented at SLEEP 2015.

Comparing the Effect of Suvorexant for Men and Women

By June 09, 2015

Suvorexant (Belsomra; Merck) 20mg/15mg and 40mg/30mg tablets were generally effective and well tolerated by both women and men with insomnia, according to a subgroup analysis of Phase 3 data presented at SLEEP 2015.

Patients, Docs Agree on Disease Status Change with Novel Narcolepsy Agent

By June 09, 2015

Clinician- and patient-reported assessments of global impression of change in disease status had "good concordance" for narcolepsy treated with JZP-110, a novel wake-promoting agent, according to results of a post hoc analysis reported at SLEEP 2015.

Lacosamide May Be Effective Option for Nocturnal Epilepsy

By June 09, 2015

In patients with treatment-resistant nocturnal frontal lobe epilepsy (NFLE), lacosamide may be an effective option, researchers concluded at SLEEP 2015.

Selective OX2R Antagonist May Be Promising for Insomnia

By June 09, 2015

Further clinical investigation of the selective high affinity/potent dual orexin-2 receptor antagonist (OX2R) JNJ-42847922 is supported by preclinical and Phase 1 clinical data, a characterization of the agent presented at SLEEP 2015 has found.

The Effects of Sodium Oxybate on Patients With Narcolepsy Without Cataplexy

By June 09, 2015

Sodium oxybate (Xyrem; Jazz), alone or in combination with modafinil, improved excessive sleepiness in patients with narcolepsy both with and without cataplexy, results of a retrospective analysis of Phase 3 randomized trial data presented at SLEEP 2015 has found.

First Study to Evaluate Sodium Oxybate in Peds With Narcolepsy, Cataplexy

June 09, 2015

The first formal randomized, placebo-controlled trial to evaluate sodium oxybate for the treatment of children and adolescents with narcolepsy and cataplexy is currently enrolling patients (NCT02221869), investigators reported at SLEEP 2015.

Suvorexant Reduces Insomnia Without Compromising Cognition

June 09, 2015

The blocking of orexin signaling has been shown to reduce wakefulness and promote sleep across species, reported Christopher J. Winrow, PhD of Merck Research Laboratories, West Point, PA, at SLEEP 2015.

Potassium Supplementation Improves OSA in Hypertensive Patients With Hypokalemia

June 08, 2015

Potassium chloride supplementation might improve the severity of obstructive sleep apnea (OSA) and sleep architecture in hypertensive patients with hypokalemia, according to a study presented at SLEEP 2015.

Why The Pill May Impair Sleep

June 08, 2015

Use of a combined oral contraceptive has shown to increase cortisol and adrenocorticotropic hormone concentrations, which are closely related with sleep, according to data presented at SLEEP 2015.